Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 489.00 | |
5 mg | In stock | $ 1,090.00 | |
10 mg | In stock | $ 1,480.00 | |
25 mg | In stock | $ 2,230.00 | |
50 mg | In stock | $ 2,930.00 | |
100 mg | In stock | $ 3,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 1,230.00 |
Description | Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases. |
In vitro | Pre-treatment of DNPHSA-stimulated RBL-2H3 with 10 μM Nothofagin markedly suppresses the phosphorylation of Lyn, Syk, and Akt. Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. Furthermore, Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo [1]. |
In vivo | Oral administration of matrine at 1 mg/kg per day for 7 consecutive days significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR) [2]. |
Molecular Weight | 436.41 |
Formula | C21H24O10 |
CAS No. | 11023-94-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (57.29 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nothofagin 11023-94-2 Apoptosis Immunology/Inflammation MAPK TNF ERK IL Receptor inhibitor inhibit